Becton Dickinson Obtains Exclusive Rights to Negotiate TriPath Acquisition | GenomeWeb
NEW YORK (GenomeWeb News) – Becton Dickinson has exclusive rights to negotiate an acquisition of TriPath Imaging, according to documents filed with the Securities and Exchange Commission yesterday.
As GenomeWeb News reported on Tuesday, Becton Dickinson offered  buy all outstanding TriPath shares for $9.25 each, or about $350 million. The company currently holds a 6.5-percent stake in TriPath.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.